|Articles|October 20, 2015
Rudolph Navari on Preventing CINV With Olanzapine
Author(s)Rudolph Navari
Rudolph Navari, discusses a study of olanzapine for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy.
Advertisement
Rudolph Navari, director, Cancer Care Program in Central and South America, World Health Organization, professor of medicine, Indiana University School of Medicine-South Bend, discusses a study of olanzapine for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on CURE
1
Cancer and Answering the Phone
2
Onvansertib Combo Improves Outcomes in First-Line RAS-Mutated mCRC
3
FDA Approves Darzalex Faspro-VRd For Newly Diagnosed, Transplant Ineligible Multiple Myeloma
4
Beyond Statistics: Lessons in Mindset and Action from a Cancer Survivor
5